This 1965 landmark paper asks whether acellular, devitalized, decalcified bone matrix can induce new bone when implanted into heterotopic soft tissue. Using ~70 experiments across ~300 animals, Urist characterizes the cellular sequence, chemical requirements, and host-cell origin of this process. He terms it autoinduction — the conceptual framework that would ultimately lead to the discovery and clinical application of bone morphogenetic proteins.
Every DBM product on your shelf — putty, gel, or strip. Works because of what Urist proved here: the organic matrix of bone, stripped of mineral, retains a protein-dependent signal capable of driving new bone formation from host cells alone.
When you choose between an allograft structural spacer and a DBM putty for a posterolateral fusion, you are applying this framework. The spacer provides osteoconduction and structural support; the DBM provides osteoinduction. Neither replaces autograft, which provides both plus live osteoprogenitor cells.
The protein-dependence of the signal has a direct clinical consequence that Urist's framework predicts: the inductive activity is saturable and sensitive to processing. Not all DBM products are equivalent. Sterilization methods that denature protein (e.g., gamma irradiation at high dose, harsh chemical treatment) degrade osteoinductive potency, which is why batch-to-batch variability in commercial DBM is a real clinical concern.
The Carragee et al. (2011) critique of rhBMP-2 in spine surgery, showing dose-dependent complications at supraphysiologic concentrations, is the logical downstream consequence of what Urist first described as a tightly regulated, microenvironment-sensitive induction system. Turning up the signal beyond physiologic levels does not simply produce more bone. It produces ectopic bone, osteolysis, and soft tissue swelling.
This 1965 landmark paper asks whether acellular, devitalized, decalcified bone matrix can induce new bone when implanted into heterotopic soft tissue. Using ~70 experiments across ~300 animals, Urist characterizes the cellular sequence, chemical requirements, and host-cell origin of this process. He terms it autoinduction — the conceptual framework that would ultimately lead to the discovery and clinical application of bone morphogenetic proteins.
Every DBM product on your shelf — putty, gel, or strip. Works because of what Urist proved here: the organic matrix of bone, stripped of mineral, retains a protein-dependent signal capable of driving new bone formation from host cells alone.
When you choose between an allograft structural spacer and a DBM putty for a posterolateral fusion, you are applying this framework. The spacer provides osteoconduction and structural support; the DBM provides osteoinduction. Neither replaces autograft, which provides both plus live osteoprogenitor cells.
The protein-dependence of the signal has a direct clinical consequence that Urist's framework predicts: the inductive activity is saturable and sensitive to processing. Not all DBM products are equivalent. Sterilization methods that denature protein (e.g., gamma irradiation at high dose, harsh chemical treatment) degrade osteoinductive potency, which is why batch-to-batch variability in commercial DBM is a real clinical concern.
The Carragee et al. (2011) critique of rhBMP-2 in spine surgery, showing dose-dependent complications at supraphysiologic concentrations, is the logical downstream consequence of what Urist first described as a tightly regulated, microenvironment-sensitive induction system. Turning up the signal beyond physiologic levels does not simply produce more bone. It produces ectopic bone, osteolysis, and soft tissue swelling.